Surge in Instrument Sales Helps Qiagen Post 21-Percent Revenue Growth in Q4 | GenomeWeb
NEW YORK (GenomeWeb News) — Qiagen today said fourth-quarter revenue rose 21 percent as R&D spending increased 14 percent and net income widened 15 percent.
 
Total receipts for the three months ended Dec. 31, 2006, rose to $125.9 million from $104.3 million year over year. The increase was in part caused by a 47-percent increase in instruments sales, the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.